Dose Dense Carboplatin, Taxotere and Herceptin As Primary Systemic Therapy in Breast Cancer
Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
Dose dense therapy has been shown to increase survival in the adjuvant setting of breast
cancer. It is unknown if dose dense therapy will improve survival in tumors that express
her-2. This study evaluates a neoadjuvant regimen containing carboplatin, taxotere and
herceptin when used in a dose dense manner in patients with large breast cancers. The
endpoint of pathologic complete response is used as a surrogate marker for survival.